المؤلفون: Gerdes, Sascha, Staubach, Petra, Dirschka, Thomas, Wetzel, Dieter, Weirich, Oliver, Niesmann, Johannes, da Mota, Rodrigo, Rothhaar, Alex, Ardabili, Michael, Vlasitz, Gerda, Feldwisch, Joachim, Koskinen, Lisa Osterling, Ohlman, Sven, Peloso, Paul M., Brun, Nikolai C., Frejd, Fredrik Y.

المصدر: British Journal of Dermatology. 189(4):381-391

وصف الملف: electronic

الوصول الحر: https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-512856Test
https://doi.org/10.1093/bjd/ljad186Test
https://uu.diva-portal.org/smash/get/diva2:1801271/FULLTEXT01.pdfTest

المؤلفون: Vastert, Sebastiaan J., Jamilloux, Yvan, Quartier, Pierre, Ohlman, Sven, Osterling Koskinen, Lisa, Kullenberg, Torbjörn, Franck-Larsson, Karin, Fautrel, Bruno, De Benedetti, Fabrizio

المساهمون: CTI Van Loosdregt, Immuno/reuma onderzoek 5 (Vastert2), Child Health, Infection & Immunity

مصطلحات موضوعية: adult-onset Still's disease (AOSD), anakinra, IL-1, IL-1 receptor antagonist (IL-1Ra), Still's disease, systemic juvenile idiopathic arthritis (sJIA), Rheumatology, Pharmacology (medical)

وصف الملف: image/pdf

العلاقة: https://dspace.library.uu.nl/handle/1874/392479Test

الإتاحة: https://dspace.library.uu.nl/handle/1874/392479Test

المؤلفون: Vastert, Sebastiaan, J, Jamilloux, Yvan, Quartier, Pierre, Ohlman, Sven, Osterling Koskinen, Lisa, Kullenberg, Torbjörn, Franck-Larsson, Karin, Fautrel, Bruno, de Benedetti, Fabrizio

المساهمون: University Medical Center Utrecht (UMCU), Hospices Civils de Lyon (HCL), Hôpital de la Croix-Rousse CHU - HCL, Service d'immuno-hématologie pédiatrique CHU Necker, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Necker - Enfants Malades AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5), CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), IRCCS Ospedale Pediatrico Bambino Gesù = Bambino Gesù Children’s Hospital

المصدر: ISSN: 1462-0324.

مصطلحات موضوعية: IL-1, IL-1 receptor antagonist (IL-1Ra), Still’s disease, adult-onset Still’s disease (AOSD), anakinra, systemic juvenile idiopathic arthritis (sJIA), [SDV]Life Sciences [q-bio], [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31769856; hal-02426584; https://hal.sorbonne-universite.fr/hal-02426584Test; https://hal.sorbonne-universite.fr/hal-02426584/documentTest; https://hal.sorbonne-universite.fr/hal-02426584/file/kez350.pdfTest; PUBMED: 31769856; PUBMEDCENTRAL: PMC6878842

الإتاحة: https://doi.org/10.1093/rheumatology/kez350Test
https://hal.sorbonne-universite.fr/hal-02426584Test
https://hal.sorbonne-universite.fr/hal-02426584/documentTest
https://hal.sorbonne-universite.fr/hal-02426584/file/kez350.pdfTest

المؤلفون: Saag, Kenneth G., Khanna, Puja P., Keenan, Robert T., Ohlman, Sven, Osterling Koskinen, Lisa, Sparve, Erik, Åkerblad, Ann‐charlotte, Wikén, Margareta, So, Alexander, Pillinger, Michael H., Terkeltaub, Robert

مصطلحات موضوعية: Rheumatology, Health Sciences

وصف الملف: application/pdf

العلاقة: Saag, Kenneth G.; Khanna, Puja P.; Keenan, Robert T.; Ohlman, Sven; Osterling Koskinen, Lisa; Sparve, Erik; Åkerblad, Ann‐charlotte; Wikén, Margareta; So, Alexander; Pillinger, Michael H.; Terkeltaub, Robert (2021). "A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares." Arthritis & Rheumatology (8): 1533-1542.; https://hdl.handle.net/2027.42/168527Test; Arthritis & Rheumatology; Mitha E, Schumacher HR, Fouche L, Luo SF, Weinstein SP, Yancopoulos GD, et al. Rilonacept for gout flare prevention during initiation of uric acid- lowering therapy: results from the PRESURGE- 2 international, phase 3, randomized, placebo- controlled trial. Rheumatology (Oxford) 2013; 52: 1285 - 92.; Tran AP, Edelman J. Interleukin- 1 inhibition by anakinra in refractory chronic tophaceous gout. Int J Rheum Dis 2011; 14: e33 - 7.; Hirsch JD, Gnanasakthy A, Lale R, Choi K, Sarkin AJ. Efficacy of canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis- related health outcomes measures. Int J Clin Pract 2014; 68: 1503 - 7.; Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active- controlled, double- blind trials and their initial extensions. Ann Rheum Dis 2012; 71: 1839 - 48.; Schlesinger N, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab relieves symptoms of acute flares and improves health- related quality of life in patients with difficult- to- treat gouty arthritis by suppressing inflammation: results of a randomized, dose- ranging study. Arthritis Res Ther 2011; 13: R53.; Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double- blind, randomised study. Ann Rheum Dis 2011; 70: 1264 - 71.; So A, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult- to- treat gouty arthritis: results of a multicenter, phase II, dose- ranging study. Arthritis Rheum 2010; 62: 3064 - 76.; Solomon DH, Glynn RJ, MacFadyen JG, Libby P, Thuren T, Everett BM, et al. Relationship of interleukin- 1β blockade with incident gout and serum uric acid levels: exploratory analysis of a randomized controlled trial. Ann Intern Med 2018; 169: 535 - 42.; Aouba A, Deshayes S, Frenzel L, Decottignies A, Pressiat C, Bienvenu B, et al. Efficacy of anakinra for various types of crystal- induced arthritis in complex hospitalized patients: a case series and review of the literature. Mediators Inflamm 2015; 2015: 792173.; Ghosh P, Cho M, Rawat G, Simkin PA, Gardner GC. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken) 2013; 65: 1381 - 4.; Ottaviani S, Molto A, Ea HK, Neveu S, Gill G, Brunier L, et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther 2013; 15: R123.; So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL- 1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9: R28.; Pascart T, Norberciak L, Ea HK, Graf S, Guggenbuhl P, Liote F. Difficult- to- treat gout flares: eligibility for interleukin- 1 inhibition in private practice is uncommon according to current EMA approval. Rheumatology (Oxford) 2019; 58: 2181 - 7.; FitzGerald JD, Dalbeth N, Mikuls T, Brignardello- Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol 2020; 72: 879 - 95.; Janssen CA, Oude Voshaar MA, Vonkeman HE, Jansen T, Janssen M, Kok MR, et al. Anakinra for the treatment of acute gout flares: a randomized, double- blind, placebo- controlled, active- comparator, non- inferiority trial. Rheumatology (Oxford) 2019; 58: 1344 - 52.; Schumacher HR Jr, Evans RR, Saag KG, Clower J, Jennings W, Weinstein SP, et al. Rilonacept (interleukin- 1 trap) for prevention of gout flares during initiation of uric acid- lowering therapy: results from a phase III randomized, double- blind, placebo- controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) 2012; 64: 1462 - 70.; Schumacher HR Jr, Sundy JS, Terkeltaub R, Knapp HR, Mellis SJ, Stahl N, et al. Rilonacept (interleukin- 1 trap) in the prevention of acute gout flares during initiation of urate- lowering therapy: results of a phase II randomized, double- blind, placebo- controlled trial. Arthritis Rheum 2012; 64: 876 - 84.; Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo- controlled, monosequence crossover, non- randomised, single- blind pilot study. Ann Rheum Dis 2009; 68: 1613 - 7.; Terkeltaub RA, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J, et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther 2013; 15: R25.; Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative [published erratum appears in Arthritis Rheumatol 2016;68:515]. Arthritis Rheumatol 2015; 67: 2557 - 68.; Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin- 1 receptor antagonist, in combination with methotrexate: results of a twenty- four- week, multicenter, randomized, double- blind, placebo- controlled trial. Arthritis Rheum 2002; 46: 614 - 24.; Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1006 - 12.; Wiken M, Hallen B, Kullenberg T, Koskinen LO. Development and effect of antibodies to anakinra during treatment of severe CAPS: sub- analysis of a long- term safety and efficacy study. Clin Rheumatol 2018; 37: 3381 - 6.; Kineret (anakinra) prescribing information. Stockholm (Sweden): Sobi; 2001. URL: https://wwwaccessdatafdagov/drugsatfda_docs/label/2012/103950s5136lblpdfTest.; Singh JA, Taylor WJ, Dalbeth N, Simon LS, Sundy J, Grainger R, et al. OMERACT endorsement of measures of outcome for studies of acute gout. J Rheumatol 2014; 41: 569 - 73.; Janssen CA, Voshaar MA, Klooster PM, Vonkeman HE, van de Laar M. Development and validation of a patient- reported gout attack intensity score for use in gout clinical studies. Rheumatology (Oxford) 2019; 58: 1928 - 34.; Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1447 - 61.; Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J, et al. 2018 updated European League Against Rheumatism evidence- based recommendations for the diagnosis of gout. Ann Rheum Dis 2020; 79: 31 - 8.; Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra- s efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 2010; 40: 210 - 4.; Gratton SB, Scalapino KJ, Fye KH. Case of anakinra as a steroid- sparing agent for gout inflammation. Arthritis Rheum 2009; 61: 1268 - 70.; Keenan RT, O- Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011; 124: 155 - 63.; Thueringer JT, Doll NK, Gertner E. Anakinra for the treatment of acute severe gout in critically ill patients. Semin Arthritis Rheum 2015; 45: 81 - 5.

الإتاحة: https://doi.org/10.1002/art.41699Test
https://hdl.handle.net/2027.42/168527Test

المؤلفون: Borg, Anette Johansson, Ohlman, Sven

المصدر: Transplant International ; volume 5, issue 4, page 219-225 ; ISSN 0934-0874 1432-2277

مصطلحات موضوعية: Transplantation

الإتاحة: https://doi.org/10.1111/j.1432-2277.1992.tb01750.xTest

المؤلفون: Lewensohn‐Fuchs, Ilona, Wester, Daniele, Bistoletti, Peter, Elfgren, Kristina, Ohlman, Sven, Dillner, Joakim, Dalianis, Tina

المصدر: Journal of Medical Virology ; volume 40, issue 3, page 188-192 ; ISSN 0146-6615 1096-9071

الإتاحة: https://doi.org/10.1002/jmv.1890400304Test

المؤلفون: LINDHOLM, ANDERS, OHLMAN, SVEN, ALBRECHTSEN, DAGFINN, TUFESON, GUNNAR, PERSSON, HANS, PERSSON, NILS H.

المصدر: Transplantation ; volume 56, issue 2, page 307-315 ; ISSN 0041-1337

الإتاحة: https://doi.org/10.1097/00007890-199308000-00010Test
http://journals.lww.com/00007890-199308000-00010Test

المؤلفون: Karuppan, Suchitra Sumitran, Ohlman, Sven, Möller, Erna

المصدر: Transplantation ; volume 54, issue 5, page 839-843 ; ISSN 0041-1337

الإتاحة: https://doi.org/10.1097/00007890-199211000-00014Test
http://journals.lww.com/00007890-199211000-00014Test

المؤلفون: Aschan, Johan, Ringdén, Olle, Ljungman, Per, Lönnqvist, Berit, Ohlman, Sven

المصدر: Scandinavian Journal of Infectious Diseases ; volume 24, issue 2, page 143-150 ; ISSN 0036-5548 1651-1980

الإتاحة: https://doi.org/10.3109/00365549209052604Test

المؤلفون: LINDHOLM, ANDERS, OHLMAN, SVEN, ALBRECHTSEN, DAGFINN, TUFESON, GUNNAR, PERSSON, HANS, PERSSON, NILS H.

المصدر: Transplantation; August 1993, Vol. 56 Issue: 2 p307-315, 9p